Management of Complicated Enteritis

Initial Assessment and Classification

The American Society of Clinical Oncology recommends evaluating a patient's hydration status through physical examination, including assessment for fever, orthostatic symptoms, weakness, and abdominal pain/cramping, to determine the severity of enteritis 3
Patients with ongoing pain and nausea should be classified as having "complicated" enteritis, which is a risk factor indicating the need for more aggressive management, according to the Journal of Clinical Oncology guidelines 3, 1
Assessing stool composition, frequency, and presence of blood or nocturnal diarrhea is crucial to determine the severity of enteritis 3

The American College of Physicians recommends administering intravenous fluids to correct dehydration and maintain fluid balance in patients with complicated enteritis 1, 2
For severe dehydration, the Infectious Diseases Society of America suggests using isotonic intravenous fluids such as lactated Ringer's or normal saline until pulse, perfusion, and mental status normalize 4
Once rehydrated, maintenance fluids should be used to replace ongoing losses, as recommended by the Clinical Infectious Diseases guidelines 4

The National Comprehensive Cancer Network recommends administering dopamine receptor antagonists such as prochlorperazine, haloperidol, or metoclopramide for persistent nausea in patients with complicated enteritis 5, 6
For refractory nausea, the Journal of the National Comprehensive Cancer Network suggests adding 5-HT3 receptor antagonists, which have lower rates of CNS effects 5, 6
Olanzapine may be particularly helpful for patients with bowel obstruction, according to the Journal of the National Comprehensive Cancer Network guidelines 6

The Annals of Oncology recommends initiating octreotide at a starting dose of 100-150 μg SC three times daily or IV (25-50 μg/h) if severely dehydrated, to control diarrhea in patients with complicated enteritis 1, 2
The dose of octreotide can be escalated up to 500 μg SC three times daily until diarrhea is controlled, as suggested by the Annals of Oncology guidelines 1, 2

The Annals of Oncology recommends administering broad-spectrum antibiotics for complicated enteritis, with consideration of combination with metronidazole if anaerobic coverage is needed 1, 2, 7, 8
The choice of antimicrobial therapy should be based on the origin of infection and severity of illness, according to the Clinical Infectious Diseases guidelines 7

A complete blood count and electrolyte profile should be performed, as recommended by the Annals of Oncology guidelines 1, 2
Stool evaluation for blood, fecal leukocytes, Clostridium difficile, Salmonella, E. coli, Campylobacter, and infectious colitis is crucial, according to the Annals of Oncology guidelines 1, 2
Abdominal imaging should be considered if there is concern for bowel obstruction or perforation, as suggested by the Clinical Infectious Diseases guidelines 7

The Annals of Oncology recommends considering neutropenic enterocolitis and initiating more aggressive management in neutropenic patients with complicated enteritis 1, 2
Broad-spectrum antibiotics, G-CSF, and nasogastric decompression should be administered, according to the Annals of Oncology guidelines 1
Surgical consultation should be considered for patients with evidence of bowel perforation, as recommended by the Clinical Infectious Diseases guidelines 7

The Journal of Clinical Oncology recommends continuing intervention until the patient has been diarrhea-free for 24 hours in cancer patients with treatment-related enteritis 3
For patients with chemotherapy-induced enteritis who progress to grade 3 or 4 diarrhea after 24-48 hours on loperamide, aggressive treatment with octreotide and antibiotics is recommended, according to the Journal of Clinical Oncology guidelines 3

Vital signs, mental status, and hydration status should be monitored closely, as recommended by the Journal of Clinical Oncology and Annals of Oncology guidelines 3, 1
Response to therapy should be assessed by tracking frequency of diarrhea, pain levels, and nausea, according to the Journal of Clinical Oncology guidelines 3
Aggressive management should be continued until symptoms resolve, as suggested by the Annals of Oncology guidelines 1, 2